$NTRA

Chapman Steven Leonard sold $1.5M of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 6,500 shares of Natera, Inc. (NTRA) at $223.34 ($1.45M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jun 6, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 6, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure provides a datapoint on insider activity but does not, by itself, indicate a change in business outlook or new fundamental information.

02

Market read

Traders may treat this as a low-signal sentiment input rather than a standalone catalyst.

03

What to watch

The filing date (June 5) may lag the actual sale (June 4), and the disclosed sale price may already be reflected in trading if the market anticipated routine 10b5-1 activity.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed June 5 for a June 4 sale

Background

SEC Form 4 reports insider transactions by officers/directors; 10b5-1 plans are pre-arranged trading schedules intended to reduce timing-based inference.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CEO and President Chapman Steven Leonard sold $1.45M of NTRA shares via an open-market transaction under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is more about sentiment than fundamentals.

Evidence & confidence

This is an SEC Form 4 insider transaction with disclosed price/size, but it is explicitly tied to a pre-arranged 10b5-1 plan, which typically dampens interpretive value.

Market effects

Minimal; this is company-specific insider execution rather than a sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can still coincide with management caution or liquidity needs; traders may watch for follow-on sales.

Key entities

  • Natera, Inc.

    Subject of the insider sale; CEO and President sold 6,500 shares for ~$1.45M under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.